METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation

Yang Yu, Yanan Hai, Hongfeng Zhou, Wenfang Bao, Xiaowei Hu, Yong Gao, Jin WuJournal of Cancer 2024 · DOI

TL;DR

This study identifies a novel therapeutic strategy for colorectal cancer (CRC) by demonstrating that inhibiting METTL3 with STM2457 suppresses CRC cell growth and survival. The mechanism involves the downregulation of asparagine synthetase (ASNS) through reduced m6A modification of ASNS mRNA, suggesting both STM2457 and ASNS as potential therapeutic targets.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant global health challenge with high mortality rates, and current therapeutic approaches often fall short. While RNA modifications, particularly N6-methyladenosine (m6A), are increasingly recognized for their role in cancer progression, the specific mechanisms by which m6A regulators like Methyltransferase-like 3 (METTL3) impact CRC are not fully understood. This paper aims to elucidate the role of METTL3 inhibition using a novel small molecule inhibitor, STM2457, in CRC and to uncover its underlying molecular mechanisms.

Methods

The researchers employed a multi-faceted approach to investigate the effects of STM2457 on CRC cells:

  • Cellular Assays: CCK-8 and colony formation assays were used to assess cell proliferation and growth. Flow cytometry and TUNEL assays were utilized to quantify apoptosis.
  • Molecular Mechanisms: RNA sequencing (RNA-seq) was performed to identify differentially expressed genes. Quantitative real-time PCR (qRT-PCR) and Western blotting were used to validate gene and protein expression changes.
  • m6A Modification Analysis: To understand the role of m6A, the study used:
  • Dual-luciferase reporter assays: To investigate the impact of m6A modification on gene activity.
  • RNA stability assays: Using actinomycin D to measure mRNA half-life.
  • MeRIP-qPCR and m6A dot blotting: To directly assess m6A modification levels on specific mRNAs.
  • In Vivo Studies: Xenograft mouse models were established to evaluate the anti-tumor efficacy of STM2457 and the role of ASNS in vivo.
  • Bioinformatics Analysis: Publicly available datasets (TCGA and GEPIA) were analyzed to correlate gene expression with clinical outcomes in CRC patients.

Datasets

  • CRC Cell Lines: HCT116 and SW620 cell lines were used for in vitro experiments.
  • Animal Models: Athymic nude mice were used to establish subcutaneous xenograft models.
  • Public Databases: The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) were used for clinical data analysis.

Key Insights and Ideas

  • METTL3 as a CRC Target: The study strongly implicates METTL3 as a key player in CRC progression, making its inhibition a promising therapeutic avenue.
  • ASNS as a Downstream Effector: The identification of Asparagine Synthetase (ASNS) as a significantly downregulated gene upon METTL3 inhibition is a crucial finding. This suggests that ASNS is a critical mediator of METTL3's effects in CRC.
  • m6A Regulation of ASNS: The paper provides compelling evidence that METTL3 regulates ASNS expression through m6A modification of ASNS mRNA. This highlights a specific molecular mechanism linking METTL3 activity to ASNS levels.
  • ASNS Overexpression Rescues Phenotypes: The ability of ASNS overexpression to partially reverse the anti-cancer effects of STM2457 underscores its central role in the observed outcomes.
  • Clinical Relevance: The correlation of high ASNS expression with worse prognosis in CRC patients adds significant clinical weight to the findings, suggesting ASNS as a potential biomarker and therapeutic target.

Key Results

  • In Vitro Efficacy: STM2457 significantly inhibited the proliferation and induced apoptosis of HCT116 and SW620 CRC cells in a dose-dependent manner.
  • In Vivo Efficacy: STM2457 treatment led to smaller tumor volumes, slower growth, and reduced tumor weight in xenograft mouse models. Histological analysis confirmed reduced proliferation (Ki67 staining) and increased apoptosis (TUNEL staining) in tumors treated with STM2457.
  • ASNS Downregulation: Both STM2457 treatment and METTL3 knockdown led to a significant decrease in ASNS mRNA and protein levels in CRC cells. Conversely, METTL3 overexpression increased ASNS levels.
  • m6A Mechanism: STM2457 and METTL3 knockdown reduced m6A modification levels in ASNS mRNA, impacting its stability and ultimately leading to its downregulation.
  • ASNS Rescue Effect: Overexpression of ASNS in CRC cells attenuated the anti-proliferative and pro-apoptotic effects of STM2457 in vitro and partially reversed the anti-tumor effects of STM2457 in vivo.
  • Clinical Correlation: ASNS was found to be highly expressed in CRC tissues compared to normal tissues, and high ASNS expression was associated with a worse prognosis.

Limitations and Future Work

  • Animal Model Specificity: The authors acknowledge that the animal model used (subcutaneous xenografts) is relatively simple and suggest the use of more diverse animal models for future in-depth research.
  • Broader Implications of ASNS: While the study focuses on the METTL3-ASNS axis, the authors suggest further investigation into how this axis might influence drug resistance and immune responses in CRC.
  • Clinical Translation: The study provides strong preclinical evidence for STM2457 as a potential therapeutic agent. Future work would involve clinical trials to validate these findings in human patients.
  • Detailed m6A Site Analysis: While a key m6A site on ASNS was identified and studied, further exploration of other potential m6A sites and their roles could provide a more comprehensive understanding.

Summary updated

Abstract

<b>Background:</b> Colorectal cancer (CRC) presents a significant global health burden, with high rates of incidence and mortality, and an urgent need to improve prognosis. STM2457, a novel small molecule inhibitor specific for N6-methyladenosine (m6A) catalytic enzyme Methyltransferase-like 3 (METTL3) has implicated significant treatment potentials in a few of types of cancer. However, its impact and underlying mechanism are still unclear in CRC cells. <b>Methods:</b> We used CCK-8 and colony formation assay to observe cell growth, flow cytometry and TUNEL approaches to detect cell apoptosis under the treatment of STM2457 on CRC cells <i>in vitro</i> or <i>in vivo</i>. RNA-sequencing, qRT-PCR and western blotting were performed to explore downstream effectors of STM2457. Messenger RNA stability was evaluated by qRT-PCR after treatment with actinomycin D. The methylated RNA immunoprecipitation (MeRIP) qPCR, dual-luciferase reporter analyses and m6A dot blotting were carried out to measure the m6A modification. Associated gene expression pattern and clinical relevance in CRC clinical tissue samples were analyzed using online database. <b>Results:</b> STM2457 exhibited a strong influence on cell growth suppression and apoptosis of CRC cells <i>in vitro</i> and subcutaneous xenograft growth <i>in vivo</i>. Asparagine synthetase (ASNS) was markedly downregulated upon STM2457 treatment or METTL3 knockdown and exogenous overexpression of ASNS could rescue the biological defects induced by STM2457. Mechanistically, the downregulation of ASNS by STM2457 may be due to the decrease of m6A modification level in ASNS mRNA mediated by METTL3. <b>Conclusions:</b> Our findings suggest that STM2457 may serve as a potential therapeutic agent and ASNS may be a new promising therapeutic target for CRC.
BibTeX
@article{yu2024mettl,
  author = {Yang Yu and Yanan Hai and Hongfeng Zhou and Wenfang Bao and Xiaowei Hu and Yong Gao and Jin Wu},
  title = {{METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation}},
  journal = {Journal of Cancer},
  year = {2024},
  doi = {10.7150/jca.96760},
}
Figure